PD-1抑制剂联合常规化疗对肺癌患者疾病控制与生存期的影响

Effect of PD-1 Inhibitors Combined with Conventional Chemotherapy on Disease Control and Survival in Patients with Lung Cancer

目的 分析肺癌患者使用程序性细胞死亡蛋白-1(programmed death-1, PD-1)抑制剂联合常规化疗的临床效果。方法 非随机选取2021年1月—2022年12月沛县人民医院收治的80例肺癌患者为研究对象。按治疗方法分为两组,常规化疗的40例纳入对照组,常规化疗联合PD-1抑制剂治疗的40例纳入观察组。比较两组疾病控制率、免疫指标、无进展生存期及不良反应发生率。结果 观察组疾病控制率为82.50%(33/40),高于对照组的60.00%(24/40),差异有统计学意义(χ^(2)=4.943,P<0.05)。观察组免疫指标水平、无进展生存期均优于对照组,差异有统计学意义(P均<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论 肺癌患者实施常规化疗联合PD-1抑制剂治疗效果更佳,对患者免疫功能影响较小,可延长其生存期,且不会增加不良反应。

Objective To analyze the clinical effects of using programmed death-1(PD-1)inhibitors in combination with conventional chemotherapy in lung cancer patients.Methods Eighty cases of lung cancer patients admitted to Peixian People's Hospital from January 2021 to December 2022 were non-randomly selected as research subjects.They were divided into two groups according to treatment methods,forty cases of conventional chemotherapy were in-cluded in the control group,and forty cases of conventional chemotherapy combined with PD-1 inhibitor treatment were included in the observation group.Disease control rate,immune index,progression-free survival and incidence of adverse reactions were compared between the two groups.Results The disease control rate of the observation group was 82.50%(33/40),which was higher than 60.00%(24/40)of the control group,and the difference was statistically sig-nificant(χ^(2)=4.943,P<0.05).The levels of immune indexes and progression-free survival of the observation group were better than those of the control group,and the differences were statistically significant(all P<0.05).There was no statis-tically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The implementation of conventional chemotherapy combined with PD-1 inhibitor treatment in lung cancer patients is more effective,has less impact on the immune function of patients,prolongs their survival,and does not increase adverse ef-fects.